U.S. markets closed

Aytu BioPharma, Inc. (AYTU)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5718+0.0198 (+3.59%)
At close: 04:00PM EDT
0.5556 -0.02 (-2.83%)
After hours: 07:37PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.5520
Bid0.5556 x 800
Ask0.5799 x 1000
Day's Range0.5420 - 0.5859
52 Week Range0.4500 - 6.1800
Avg. Volume1,011,966
Market Cap22.057M
Beta (5Y Monthly)-0.12
PE Ratio (TTM)N/A
EPS (TTM)-4.2400
Earnings DateMay 16, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AYTU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aytu BioPharma, Inc.
    ANIP: Raising target price to $24.00ANI PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $24.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    11 days agoArgus Research
View more
  • Benzinga

    Aytu BioPharma Plans To Divest / Discontinue Non Core Assets

    View more earnings on AYTUSee more from BenzingaFDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYTWarren Buffett Exits Wells Fargo And Buys Stake In Its Rival BankDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga does not provide investment advice. All rights reserved.


    Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities

    Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company HistoryStrategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and Performance and Preparing Pipeline for Long-term Value CreationENGLEWOOD, CO / ACCESSWIRE / May 16, 2022 / Aytu BioPharma, Inc.


    Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology

    Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated PneumoniaENGLEWOOD, CO / ACCESSWIRE / April 25, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced positive results from a preclinical pilot study showing that administration of its Healight™ ultraviolet light A (UVA) endotracheal catheter delayed the time to development of